Diabetic Nephropathy (Metabolic Disorder) - Drugs In Development, 2021

July 2021 | 340 pages | ID: D53433B34650EN
Global Markets Direct

Abstracts

Diabetic Nephropathy (Metabolic Disorder) - Drugs In Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Nephropathy - Drugs In Development, 2021, provides an overview of the Diabetic Nephropathy (Metabolic Disorders) pipeline landscape.

Diabetic nephropathy is the damage to the kidney occurring due to diabetes. It is characterized by albuminuria, reduction in glomerular filtration rate and high blood pressure. Risk factors include obesity, hypertension, high lipid and sugar levels and smoking. This condition is managed by medication and dietary modification.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Nephropathy - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Diabetic Nephropathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Nephropathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Nephropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 32, 9, 1, 37 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Diabetic Nephropathy (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Nephropathy (Metabolic Disorders).
• The pipeline guide reviews pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Diabetic Nephropathy (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Diabetic Nephropathy (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Nephropathy (Metabolic Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Diabetic Nephropathy (Metabolic Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Diabetic Nephropathy (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Diabetic Nephropathy - Overview
Diabetic Nephropathy - Therapeutics Development
Diabetic Nephropathy - Therapeutics Assessment
Diabetic Nephropathy - Companies Involved in Therapeutics Development
Diabetic Nephropathy - Drug Profiles
Diabetic Nephropathy - Dormant Projects
Diabetic Nephropathy - Discontinued Products
Diabetic Nephropathy - Product Development Milestones
Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Diabetic Nephropathy, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Diabetic Nephropathy - Pipeline by Aerpio Pharmaceuticals Inc, 2021
Diabetic Nephropathy - Pipeline by AIBIOS Co Ltd, 2021
Diabetic Nephropathy - Pipeline by Akebia Therapeutics Inc, 2021
Diabetic Nephropathy - Pipeline by Algomedix Inc, 2021
Diabetic Nephropathy - Pipeline by Antisense Therapeutics Ltd, 2021
Diabetic Nephropathy - Pipeline by APT Therapeutics Inc, 2021
Diabetic Nephropathy - Pipeline by AptaBio Therapeutics Inc, 2021
Diabetic Nephropathy - Pipeline by Araim Pharmaceuticals Inc, 2021
Diabetic Nephropathy - Pipeline by Astellas Pharma Inc, 2021
Diabetic Nephropathy - Pipeline by AstraZeneca Plc, 2021
Diabetic Nephropathy - Pipeline by Bayer AG, 2021
Diabetic Nephropathy - Pipeline by Betagenon AB, 2021
Diabetic Nephropathy - Pipeline by Bird Rock Bio Inc, 2021
Diabetic Nephropathy - Pipeline by BLR Bio LLC, 2021
Diabetic Nephropathy - Pipeline by Boehringer Ingelheim International GmbH, 2021
Diabetic Nephropathy - Pipeline by Bristol-Myers Squibb Co, 2021
Diabetic Nephropathy - Pipeline by Caladrius Biosciences Inc, 2021
Diabetic Nephropathy - Pipeline by CCRP Therapeutics GmbH, 2021
Diabetic Nephropathy - Pipeline by Cellmid Ltd, 2021
Diabetic Nephropathy - Pipeline by Certa Therapeutics Pty Ltd, 2021
Diabetic Nephropathy - Pipeline by ChemoCentryx Inc, 2021
Diabetic Nephropathy - Pipeline by Chinook Therapeutics Inc, 2021
Diabetic Nephropathy - Pipeline by Corbus Pharmaceuticals Inc, 2021
Diabetic Nephropathy - Pipeline by CSL Ltd, 2021
Diabetic Nephropathy - Pipeline by cStem Regeneration Pharmaceutical Co Ltd, 2021
Diabetic Nephropathy - Pipeline by Curacle Co Ltd, 2021
Diabetic Nephropathy - Pipeline by Slate Bio Inc, 2021
Diabetic Nephropathy - Pipeline by Sulfateq BV, 2021
Diabetic Nephropathy - Pipeline by Teijin Pharma Ltd, 2021
Diabetic Nephropathy - Pipeline by Unicyte AG, 2021
Diabetic Nephropathy - Pipeline by Vidasym Inc, 2021
Diabetic Nephropathy - Pipeline by Wuhan Hamilton Bio-technology Co Ltd, 2021
Diabetic Nephropathy - Pipeline by Wuhan LL Science and Technology Development Co Ltd, 2021
Diabetic Nephropathy - Pipeline by ZyVersa Therapeutics Inc, 2021
Diabetic Nephropathy - Dormant Projects, 2021
Diabetic Nephropathy - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Diabetic Nephropathy, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021